Search

Newer techniques for processing bone graft materials offer significant clinical benefits to clinicians experienced with traditional HA-based xenograft materials.

One such material is Ti-oss xenograft bone.

What is Ti-oss?

Ti-oss is a highly porous bone graft scaffold derived from 100% cancellous bone of bovine origin. Unlike traditional xenografts and some mineralised allografts, Ti-oss is prepared using a chemical processing to supplement a 600-degree temperature process. This retains greater porosity than tissue treated at high heat – c 1200 degrees, which changes the surface, making it harder (less dense). A denser surface is more resilient to cellular remodelling.  The processing of Ti-oss xenograft also includes a treatment which adds an OCP-rich surface shown to stimulate osteoblastic activity. Moreover, the advanced processing ensures an average pore size 3 x that of Bio-Oss, which enhances the economic benefits due to greater defect fill per gram, as shown in the included image.

1.0g of Ti-oss is equivalent to 2.3cc. ti-oss more volume than bi-oss

Volume efficiency 0.5g. Ti-oss (L), Bi-Oss (M), Nibec (R). 

What is OCP and why is an OCP-rich surface beneficial?

OCP stands for Octacalcium phosphate. Numerous studies confirm that OCP enhances bone regeneration due to osteoblast stimulation during the conversion of OCP into HA and thus induces new bone deposition. This initial step is followed by collagen formation, apatite crystal deposition, and bone mineralisation. (1)

OCP and Ti-Oss Histology.

Osteoblasts are directly aligned on the OCP and the newly formed osteoid bone matrix. Osteoblasts are cuboidal, indicating that active synthesis of bone matrix collagen is occurring.

An osteoclast cell is seen in contact with osteoblasts and attached directly to the OCP surface, suggesting active resorption. B: newly formed bone. * OCP granule. Osteoclasts arrowed. (1)


More about Ti-oss xenograft and its predictable performance can be accessed here.


References: See manufacurers clinical library at https://www.ti-oss.com/clinicaldata